CARMIEL, Israel--(BUSINESS WIRE)--Protalix Ltd. announced today that it has advised its shareholders of its progress concerning the closing of the proposed merger of Protalix with Orthodontix, Inc., a publicly-held company controlled by Dr. Phillip Frost, former Chairman and Chief Executive Officer of IVAX Corporation. In connection with the merger, Orthodontix has confirmed that it will change its name to Protalix BioTherapeutics, Inc. Mr. Eli Hurvitz, Protalix’s chairman, will serve as Chairman of the Board and Dr. David Aviezer, the Chief Executive Officer of Protalix, will serve as the President and Chief Executive Officer of the merged company. In connection with the merger, Protalix will become a wholly-owned subsidiary of the company previously known as Orthodontix.
